Objective:To explore the clinical efficacy and safety oflumbrokinase in the treatment of acute and moderate risk pulmonary thromboembolism.Methods:The clinical data of 60 patients with acute and moderate risk pulmonary thromboembolism,who were collected from January 2010 to October 2015 in Hunan Provincial People's Hospital,were retrospectively analyzed.According to the different treatments,60 patients were randomly divided into a lumbrokinase group (lumbrokinase in combination with low molecular heparin and sequential warfarin,n=30) and a control group (low molecular heparin and sequential warfarin,n=30).The clinical efficacy and safety were compared between the two groups.Results:Compared with the control group,maximum short axis,ratio of right and left ventricles,systolic pulmonary artery pressure,and the main pulmonary artery diameter in the lumbrokinase group were significant changed after the treatment for 10,20 and 30 d.NT-proBNP level in the lumbrokinase group after the treatment for 10,20 and 30 d was significantly reduced than that in the the control group (P＜0.05).However,the value of PO2 significantly increased after 10,20 and 30 d,and there was no significant difference between 20 d and 30 d (P＞0.05).D-dimer in the two groups was obviously increased after treatment for 10 d,but it was significantly reduced after treatment for 20 d or 30 d (P＜0.05).The clinical efficacy of the lumbrokinase group was better than that in the control group,with significant difference (P＜0.05).Conclusion:Combination of lumbrokinase with low molecular heparin and sequential warfarin is a safe and efficient strategy in treating the patients with acute and moderate risk pulmonary thromboembolism.It is worthy of clinical popularization and application.

Objective To explore the efficacy and safety of rivaroxaban in the treatment of acute intermediate-risk pulmonary thromboembolism (PTE) complicated by deep vein thrombosis (DVT) of lower limbs.Methods The clinical data on 60 patients with acute intermediate-risk PTE with DVT of lower limbs who had been treated from January 2010 to March 2015 in Hunan Provincial People's Hospital were retrospectively analysed.60 patients were divided into rivaroxaban group and control group (low molecular heparin and sequential warfarin),30 in each group.Results Echocardiogrphy results showed that the right ventricular maximum short axis diameter,right to left ventricular maximum short axis diameter ratio and pulmonary artery systolic pressure significantly decreased,but the left ventricular maximum short axis diameter significantly increased after treatment on days 10,20,and 30 in rivaroxaban group and the control group,and there was no significant difference between the two groups (P ＞ 0.05 for all comparisons).NT-proBNP level was significantly reduced after treatment on days 10,20,and 30,whilePO2 value was significantly increased after treatment on days 10 and 20,and no statistical significance between the two groups (P ＞ 0.05 for all comparisons).D-dimer was obviously higher on day 10 and lower on days 20 and 30 in rivaroxaban group than that in the control group.Conclusions Treatment withrivaroxabanfor acute intermediate-risk PTE with DVT of lower limbs is effective and safe,worthy of clinical implementation and application.